Literature DB >> 10809268

Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns.

P Kienbaum1, N Scherbaum, N Thürauf, M C Michel, M Gastpar, J Peters.   

Abstract

OBJECTIVE: Mu-Opioid receptor blockade during general anesthesia is a new treatment for detoxification of opioid addicted patients. We assessed catecholamine plasma concentrations, oxygen consumption, cardiovascular variables, and withdrawal symptoms after naloxone and tested the hypothesis that variables are influenced by the anesthetic administered during detoxification.
DESIGN: Prospective randomized clinical study.
SETTING: Intensive care unit of a university hospital and psychiatric ward. PATIENTS: Twenty-five mono-opioid addicted patients with mild to moderate systemic disease (ASA II classification) in a methadone substitution program. INTERVENTION: General anesthesia with either propofol (129+/-7 microg x kg(-1) x min(-1), mean +/- SEM) or methohexital (74+/-14 microg x kg(-1). min(-1)), mu-opioid receptor blockade by naloxone in a stepwise fashion (increasing doses of 0.4 mg, 0.8 mg, 1.6 mg, 3.2 mg, and 6.4 mg at 15 min intervals followed by 0.8 mg x hr(-1) for 24 hrs) and naltrexone 50 mg x day(-1) orally for > or =4 wks. Clonidine was started 180 mins after the first naloxone dose and its infusion rate was individually adjusted to mitigate withdrawal symptoms during weaning and after extubation.
MEASUREMENTS AND MAIN RESULTS: During propofol and methohexital anesthesia, naloxone induced a 30-fold increase in epinephrine and a significant three-fold increase in norepinephrine plasma concentrations without a significant difference between groups. This increase in catecholamine plasma concentrations was associated with increased oxygen consumption and marked cardiovascular stimulation with both anesthetics, as shown by increased cardiac index, heart rate, and systolic atrial pressure whereas diastolic pressure remained unchanged. Patients receiving propofol could be extubated significantly earlier after discontinuation of the anesthetics. Although the maximum degree of withdrawal symptoms (Short Opioid Withdrawal Scale) on the day after detoxification was similar with both anesthetics, subsequent withdrawal symptoms decreased significantly more rapidly after propofol anesthesia.
CONCLUSIONS: Naloxone treatment, in opioid-addicted patients, induced a marked increase in catecholamine plasma concentrations, metabolism, and cardiovascular stimulation during anesthesia with both propofol and methohexital. Although both anesthetics appear suitable for detoxification treatment, the use of propofol is associated with earlier extubation and, surprisingly, a shortened period of long-term withdrawal symptoms during detoxification.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10809268     DOI: 10.1097/00003246-200004000-00010

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  9 in total

Review 1.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

Review 2.  Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

3.  Effect of proton pump inhibitors on gastric pH in patients exposed to severe stress.

Authors:  Kurt Lenz; Robert Buder; Fritz Firlinger; Gerald Lohr; Martin Voglmayr
Journal:  Wien Klin Wochenschr       Date:  2014-11-20       Impact factor: 1.704

4.  [Naloxone-induced pulmonary edema. Case report with review of the literature and critical evaluation].

Authors:  C L Lassen; W Zink; C H R Wiese; B M Graf; C Wiesenack
Journal:  Anaesthesist       Date:  2012-02-23       Impact factor: 1.041

5.  Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan.

Authors:  Hsin-Ya Lee; Jih-Heng Li; Li-Tzy Wu; Jin-Song Wu; Cheng-Fang Yen; Hsin-Pei Tang
Journal:  Subst Abuse Treat Prev Policy       Date:  2012-03-20

Review 6.  Pharmacological therapies for management of opium withdrawal.

Authors:  Afarin Rahimi-Movaghar; Jaleh Gholami; Laura Amato; Leila Hoseinie; Reza Yousefi-Nooraie; Masoumeh Amin-Esmaeili
Journal:  Cochrane Database Syst Rev       Date:  2018-06-21

7.  Role of Benzodiazepines in the management of agitation due to inappropriate use of naltrexone.

Authors:  Ali Mohammad Sabzghabaee; Nastaran Eizadi-Mood; Farzad Gheshlaghi; Azam Javani; Shahin Shirani; Safieh Aghaabdollahian
Journal:  Iran J Nurs Midwifery Res       Date:  2012-07

8.  Propofol in the Pediatric Intensive Care Unit, a Safe and Effective Agent in Reducing Pain and Sedation Infusions: A Single-Center Retrospective Study.

Authors:  Sruti Uppuluri; Enrique G Villarreal; Vincent Dorsey; Faeeq Yousaf; Juan S Farias; Saul Flores; Rohit S Loomba
Journal:  Cureus       Date:  2022-08-12

9.  Deaths and severe adverse events associated with anesthesia-assisted rapid opioid detoxification--New York City, 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-09-27       Impact factor: 17.586

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.